F. Pitoia, R. Chervin, S. Nuñez, M. Salvai, E. Tamer, D. Schere, H. Nièpomniszcze
{"title":"放射性碘治疗多结节性甲状腺肿大的新方案后Graves病的发展","authors":"F. Pitoia, R. Chervin, S. Nuñez, M. Salvai, E. Tamer, D. Schere, H. Nièpomniszcze","doi":"10.1097/TEN.0B013E3181C9FE34","DOIUrl":null,"url":null,"abstract":"Objective:Following radioiodine (RI) therapy for multinodular goiter (MNG), 4% to 5% of patients are reported to develop Graves' hyperthyroidism. To show a new protocol for the administration of RI in MNG and to illustrate an infrequent adverse event observed after the RI dose.Methods:A 70-year-old","PeriodicalId":50531,"journal":{"name":"Endocrinologist","volume":"32 1","pages":"7-9"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Development of Graves' Disease Following a Radioiodine Dose for the Shrinkage of a Multinodular Goiter After Using a Novel Protocol\",\"authors\":\"F. Pitoia, R. Chervin, S. Nuñez, M. Salvai, E. Tamer, D. Schere, H. Nièpomniszcze\",\"doi\":\"10.1097/TEN.0B013E3181C9FE34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective:Following radioiodine (RI) therapy for multinodular goiter (MNG), 4% to 5% of patients are reported to develop Graves' hyperthyroidism. To show a new protocol for the administration of RI in MNG and to illustrate an infrequent adverse event observed after the RI dose.Methods:A 70-year-old\",\"PeriodicalId\":50531,\"journal\":{\"name\":\"Endocrinologist\",\"volume\":\"32 1\",\"pages\":\"7-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinologist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/TEN.0B013E3181C9FE34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TEN.0B013E3181C9FE34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Development of Graves' Disease Following a Radioiodine Dose for the Shrinkage of a Multinodular Goiter After Using a Novel Protocol
Objective:Following radioiodine (RI) therapy for multinodular goiter (MNG), 4% to 5% of patients are reported to develop Graves' hyperthyroidism. To show a new protocol for the administration of RI in MNG and to illustrate an infrequent adverse event observed after the RI dose.Methods:A 70-year-old
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
